Late Frontline
1 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| Efficacy and Safety of Dalpiciclib Plus Toremifene in the Treatment of Advanced First-line HR Positive and HER2 Negative Breast Cancer: a Multicenter, Single Arm, Exploratory Phase II Clinical Study (NCT06495515) | Tianjin Medical University Cancer Institute and Hospital | 2024-08-01 |
Track Late Frontline automatically
Every clearance here is in the API, with alerts when new ones post.